

DAFTAR PUSTAKA

-Ogah, A. C. (2015) 'Hyperlipidemia: Etiology and Possible Control', *IOSR Journal of Dental and Medical Sciences*, 14(10), pp. 2279–861. doi: 10.9790/0853-1410693100.

Ama Moor, V. J. *et al.* (2017) 'Dyslipidemia in Patients with a Cardiovascular Risk and Disease at the University Teaching Hospital of Yaoundé, Cameroon', *International Journal of Vascular Medicine*. Hindawi Publishing Corporation, 2017. doi: 10.1155/2017/6061306.

Backes, J. M. *et al.* (2012) 'Does Simvastatin Cause More Myotoxicity Compared with Other Statins?', *Ann Pharmacother*, 43, pp. 2012–2020. doi: 10.1345/aph.1M410.

Baird, M. F. *et al.* (2012) 'Creatine-kinase- and exercise-related muscle damage implications for muscle performance and recovery', *Journal of Nutrition and Metabolism*, 2012. doi: 10.1155/2012/960363.

Ballard, K. D. *et al.* (2013) 'Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance', *Atherosclerosis*. Elsevier Ltd, 230(1), pp. 121–124. doi: 10.1016/j.atherosclerosis.2013.07.001.

Catapano, A. L. *et al.* (2012) 'ESC / EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European', (2011), pp. 1769–1818. doi: 10.1093/eurheartj/ehs158.

Chapman, M. J. and Carrie, A. (2015) 'Mechanisms of Statin-Induced Myopathy', *Arterioscler Thromb Vasc Biol*, 22, pp. 2441–2444. doi: 10.1161/01.ATV.0000194548.11901.a4.

Danese, E. and Montagnana, M. (2016) 'An historical approach to the diagnostic biomarkers of acute coronary syndrome', 4(8), pp. 1–11. doi: 10.21037/atm.2016.05.19.

Germany, H. G. *et al.* (2012) 'European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology', *European Heart Journal*, 33, pp. 1635–1701. doi: 10.1093/eurheartj/ehs092.

Hafidh A, A.-H. and Fox Keith A (2009) 'Cardiac markers in the Early Diagnosis and management of patients with acute coronary syndrome', 9(3), pp. 231–246.

Jose, M. A. *et al.* (2012) 'A comparative effect of atorvastatin with other statins in patients of hyperlipidemia', 44(2), pp. 261–264. doi: 10.4103/0253-7613.93864.

Joseph, J., Harish, F. and Selvakumar, A. J. R. (2011) 'Anomalous Activity

Measurements of Creatine (Phospho) Kinase , CK-MB Isoenzyme in Indian Patients in the Diagnosis of Acute Coronary Syndrome’, 26(1), pp. 32–40. doi: 10.1007/s12291-010-0089-8.

Karalis, D. G. (2017) ‘A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids’, *Advances in Therapy*. Springer Healthcare, 34(2), pp. 300–323. doi: 10.1007/s12325-016-0462-y.

Kjeldsen, S. E. (2017) ‘Hypertension and cardiovascular risk: general aspects’, *Pharmacological Research*. Elsevier Ltd, 12, pp. 95–99. doi: 10.1016/j.phrs.2017.11.003.

Kopin, L. and Lowenstein, C. (2017) ‘In the Clinic® dyslipidemia’, *Annals of Internal Medicine*, 167(11), pp. ITC81–ITC95. doi: 10.7326/AITC201712050.

Lewis, S. J. (2009) ‘Prevention and Treatment of Atherosclerosis: A Practitioner’s Guide for 2008’, *American Journal of Medicine*. Elsevier Inc. Elsevier Inc., 122(1 SUPPL.), pp. S38–S50. doi: 10.1016/j.amjmed.2008.10.016.

Lin, C. F. *et al.* (2018) ‘Epidemiology of Dyslipidemia in the Asia Pacific Region’, *International Journal of Gerontology*, 12(1), pp. 2–6. doi: 10.1016/j.ijge.2018.02.010.

Lu, H. T. *et al.* (2014) ‘Sex Differences in Acute Coronary Syndrome in a Multiethnic Asian Population’, *Global Heart*. World Heart Federation (Geneva), 9(4), pp. 381–390. doi: 10.1016/j.gheart.2014.06.001.

Madhu, K. *et al.* (2013) ‘Atherogenic dyslipidemia’, *Indian Journal of Endocrinology and Metabolism*, 17(6), p. 969. doi: 10.4103/2230-8210.122600.

Marcoff, L. and Thompson, P. D. (2007) ‘The Role of Coenzyme Q10 in Statin-Associated Myopathy A Systematic Review’, *Journal of american college of cardiology*, 49(23), pp. 2231–2237. doi: 10.1016/j.jacc.2007.02.049.

Mirghani, H. O. (2016) ‘Age related differences in acute coronary syndrome presentation and in hospital outcomes: a cross-sectional comparative study’, 24(337), pp. 1–5. doi: 10.11604/pamj.2016.24.337.8711.

Muhibbah *et al.* (2019) ‘Karakteristik Pasien Sindrom Koroner Akut Pada Pasien Rawat Inap Ruang Tulip di RSUD Ulin Banjarmasin’, *Indonesian journal for health sciences*, 3(1), pp. 6–12.

Nepal, G. *et al.* (2018) ‘Dyslipidemia and Associated Cardiovascular Risk Factors among Young Nepalese University Students’, *Cureus*, 10(1), pp. 1–10. doi: 10.7759/cureus.2089.

Neuvonen, P., Niemi, M. and Backman, J. (2006) 'Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance Lipid-lowering', *American Society for Clinical Pharmacology*, 80(6), pp. 565–581. doi: 10.1016/j.clpt.2006.09.003.

Nkoke, C. *et al.* (2017) 'A predominance of hypertensive heart disease among patients with cardiac disease in Buea , a semi - urban setting , South West Region of Cameroon', *BMC Research Notes*. BioMed Central, 10(684), pp. 1–6. doi: 10.1186/s13104-017-3034-6.

Nogueira, A. A. R. *et al.* (2019) 'Biochemical markers of muscle damage and high serum concentration of creatine kinase in patients on statin therapy', *Biomarkers in Medicine*, 13(8), pp. 619–626.

Nuzzo, A., Rossi, R. and Modena, M. G. (2015) 'Hypertension alone or related to the metabolic syndrome in postmenopausal women', 8(11), pp. 1541–1548. doi: 10.1586/erc.10.147.

PARK, J.-E. *et al.* (2008) 'Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin', 38(September), pp. 1240–1251. doi: 10.1080/00498250802334391.

Petrie, J. R., Guzik, T. J. and Touyz, R. M. (2018) 'Diabetes , Hypertension , and Cardiovascular Disease : Clinical Insights and Vascular Mechanisms', *Canadian Journal of Cardiology*. The Authors, 34(5), pp. 575–584. doi: 10.1016/j.cjca.2017.12.005.

Pretis, D., Amodio, A. and Frulloni, L. (2018) 'Hypertriglyceridemic pancreatitis : Epidemiology , pathophysiology and clinical management', *united ueropean gastroenterology journal*, pp. 1–7. doi: 10.1177/2050640618755002.

Qi, L. *et al.* (2015) 'Prevalence and risk factors associated with dyslipidemia in Chongqing, China', *International Journal of Environmental Research and Public Health*, 12(10), pp. 13455–13465. doi: 10.3390/ijerph121013455.

Ralapanawa, U. *et al.* (2019) 'Epidemiology and risk factors of patients with types of acute coronary syndrome presenting to a tertiary care hospital in Sri Lanka', *BMC Cardiovascular Disorders*. BMC Cardiovascular Disorders, 19(229), pp. 1–9.

Riskesdes (2013) 'Proporsi Obesitas Sentra Pada Umur > 15 tahun Menurut Provinsi di Indonesia Tahun 2013'. doi: 10.1017/CBO9781107415324.004.

Rosenson, R. S. *et al.* (2017) 'Optimizing Cholesterol Treatment in patients with muscle complaints', *Journal of american college of cardiology*, 70(10), pp. 1290–1301. doi: 10.1016/j.jacc.2017.07.752.

Rundek, T. *et al.* (2016) 'Atorvastatin Decreases the Coenzyme Q 10 Level in the Blood of Patients at Risk for Cardiovascular Disease and Stroke', *Arch Neurol*, 61(June 2004), pp. 889–892.

S. Mannu, G. *et al.* (2013) 'Evidence of Lifestyle Modification in the Management of Hypercholesterolemia', *Current Cardiology Reviews*, 9(1), pp. 2–14. doi: 10.2174/157340313805076313.

Sathasivam, S. and Lecky, B. (2008) 'Statin-induced myopathies', *british medical journal*, 337, pp. 1159–1162. doi: doi:10.1136/bmj.a2286.

Sethi, S. S., Akl, E. G. and Farkouh, M. E. (2012) 'Diabetes Mellitus and Acute Coronary Syndrome : Lessons From Randomized Clinical Trials', *Current Diabetes Reports - Springer*, 12, pp. 294–304. doi: 10.1007/s11892-012-0272-9.

Sharma, U. *et al.* (2013) 'Dyslipidemia and associated risk factors in a resettlement colony of Delhi', *Journal of Clinical Lipidology*. Mosby, Inc, 7(6), pp. 653–660. doi: 10.1016/j.jacl.2013.06.003.

Di Stasi, S. L. *et al.* (2010) 'Effects of Statins on Skeletal Muscle: A Perspective for Physical Therapists', *Physical Therapy*, 90(10), pp. 1530–1542. doi: 10.2522/ptj.20090251.

Stolcpart, R. S. *et al.* (2010) 'The Risk for Significant Creatine Kinase Elevation with Statins', *Am J Cardiovasc Drugs*, 10(3), pp. 187–192.

Subramanian, A. *et al.* (2013) 'Evaluation of Serum Creatine Kinase and Urinary Myoglobin as Markers in Detecting Development of Acute Renal Failure in Severely Injured Trauma Patients', *ISRN Emergency Medicine*, 2013, pp. 1–8. doi: 10.1155/2013/241036.

Teixeira, A. M. *et al.* (2012) 'Teixeira & Borges: Creatine Kinase CREATINE KINASE: STRUCTURE AND FUNCTION', *Brazilian Journal of Biomotricity*. Available at: www.brjb.com.br.

Teramoto, T. *et al.* (2013) 'Other High-Risk Conditions', *Journal of Atherosclerosis and Thrombosis*, 20(11), pp. 785–789. doi: 10.5551/jat.17525.

Verma, N. (2017) 'Introduction to hyperlipidemia and its treatment: A review', *International Journal of Current Pharmaceutical Research*, 9(1), pp. 6–14. doi: 10.22159/ijcpr.2017v9i1.16616.

Zodda, D., Giammona, R. and Schifilliti, S. (2018) 'Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs', *Pharmacy*, 6(1), p. 10. doi: 10.3390/pharmacy6010010.